Latest Insider Transactions at Cytom X Therapeutics, Inc. (CTMX)
This section provides a real-time view of insider transactions for Cytom X Therapeutics, Inc. (CTMX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CytomX Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CytomX Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 20
2024
|
Christopher Ogden Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,984
-1.8%
|
$1,984
$1.23 P/Share
|
|
Aug 20
2024
|
Christopher Ogden Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,875
+5.88%
|
-
|
|
Aug 20
2024
|
Lloyd A Rowland General Counsel |
SELL
Open market or private sale
|
Direct |
4,181
-3.1%
|
$4,181
$1.23 P/Share
|
|
Aug 20
2024
|
Lloyd A Rowland General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+7.69%
|
-
|
|
Aug 20
2024
|
Marcia Belvin SVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,181
-2.33%
|
$4,181
$1.23 P/Share
|
|
Aug 20
2024
|
Marcia Belvin SVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+5.89%
|
-
|
|
Aug 20
2024
|
Jeffrey B Landau Chief Business Officer |
SELL
Open market or private sale
|
Direct |
4,181
-3.39%
|
$4,181
$1.23 P/Share
|
|
Aug 20
2024
|
Jeffrey B Landau Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+8.37%
|
-
|
|
Aug 20
2024
|
Sean A. Mc Carthy CEO |
SELL
Open market or private sale
|
Direct |
13,898
-2.07%
|
$13,898
$1.23 P/Share
|
|
Aug 20
2024
|
Sean A. Mc Carthy CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
37,500
+5.29%
|
-
|
|
Jun 12
2024
|
Christopher Ogden Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+14.5%
|
-
|
|
Mar 26
2024
|
Sean A. Mc Carthy CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
109,768
+14.75%
|
$109,768
$1.57 P/Share
|
|
Mar 19
2024
|
Marcia Belvin SVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,795
-7.05%
|
$25,590
$2.09 P/Share
|
|
Mar 19
2024
|
Christopher Ogden Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,971
-3.35%
|
$5,942
$2.09 P/Share
|
|
Mar 19
2024
|
Sean A. Mc Carthy CEO |
SELL
Open market or private sale
|
Direct |
20,223
-3.71%
|
$40,446
$2.09 P/Share
|
|
Mar 19
2024
|
Lloyd A Rowland General Counsel |
SELL
Open market or private sale
|
Direct |
5,268
-4.28%
|
$10,536
$2.09 P/Share
|
|
Mar 19
2024
|
Jeffrey B Landau Chief Business Officer |
SELL
Open market or private sale
|
Direct |
6,562
-5.63%
|
$13,124
$2.09 P/Share
|
|
Jan 18
2024
|
Sean A. Mc Carthy CEO |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+14.18%
|
-
|
|
Jan 18
2024
|
Jeffrey B Landau Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+20.46%
|
-
|
|
Jan 18
2024
|
Christopher Ogden Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+31.09%
|
-
|
|
Jan 18
2024
|
Lloyd A Rowland General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+16.89%
|
-
|
|
Jan 18
2024
|
Yu Waye Chu Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,250
+50.0%
|
-
|
|
Jan 18
2024
|
Marcia Belvin SVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,250
+12.64%
|
-
|
|
Dec 20
2023
|
Marcia Belvin SVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,077
-2.56%
|
$4,077
$1.38 P/Share
|
|
Dec 20
2023
|
Sean A. Mc Carthy CEO |
SELL
Open market or private sale
|
Direct |
13,551
-2.89%
|
$13,551
$1.38 P/Share
|
|
Dec 20
2023
|
Christopher Ogden Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,990
-3.93%
|
$1,990
$1.38 P/Share
|
|
Dec 20
2023
|
Lloyd A Rowland General Counsel |
SELL
Open market or private sale
|
Direct |
4,077
-3.99%
|
$4,077
$1.38 P/Share
|
|
Dec 20
2023
|
Jeffrey B Landau Chief Business Officer |
SELL
Open market or private sale
|
Direct |
4,077
-4.5%
|
$4,077
$1.38 P/Share
|
|
Dec 17
2023
|
Lloyd A Rowland General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+9.93%
|
-
|
|
Dec 17
2023
|
Jeffrey B Landau Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+11.03%
|
-
|
|
Dec 17
2023
|
Sean A. Mc Carthy CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
37,500
+7.41%
|
-
|
|
Dec 17
2023
|
Christopher Ogden Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,875
+11.95%
|
-
|
|
Dec 17
2023
|
Marcia Belvin SVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+6.6%
|
-
|
|
Sep 22
2023
|
Jeffrey B Landau Chief Business Officer |
SELL
Open market or private sale
|
Direct |
4,119
-5.12%
|
$4,119
$1.3 P/Share
|
|
Sep 22
2023
|
Marcia Belvin SVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,119
-2.71%
|
$4,119
$1.3 P/Share
|
|
Sep 22
2023
|
Lloyd A Rowland General Counsel |
SELL
Open market or private sale
|
Direct |
5,486
-6.37%
|
$5,486
$1.3 P/Share
|
|
Sep 22
2023
|
Sean A. Mc Carthy CEO |
SELL
Open market or private sale
|
Direct |
14,601
-3.28%
|
$14,601
$1.3 P/Share
|
|
Sep 20
2023
|
Jeffrey B Landau Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,250
+12.26%
|
-
|
|
Sep 20
2023
|
Marcia Belvin SVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,250
+6.89%
|
-
|
|
Sep 20
2023
|
Lloyd A Rowland General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+14.84%
|
-
|
|
Sep 20
2023
|
Sean A. Mc Carthy CEO |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+8.24%
|
-
|
|
May 19
2023
|
Sean A. Mc Carthy CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,535
+3.92%
|
$16,535
$1.57 P/Share
|
|
Mar 29
2023
|
Elaine V Jones |
BUY
Open market or private purchase
|
Direct |
5,000
+49.3%
|
$5,000
$1.55 P/Share
|
|
Mar 22
2023
|
Marcia Belvin SVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+29.88%
|
-
|
|
Mar 16
2023
|
Amy C. Peterson EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,257
-6.79%
|
$4,257
$1.98 P/Share
|
|
Mar 16
2023
|
Jeffrey B Landau Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,477
-2.09%
|
$1,477
$1.98 P/Share
|
|
Mar 16
2023
|
Lloyd A Rowland General Counsel |
SELL
Open market or private sale
|
Direct |
2,037
-2.79%
|
$2,037
$1.98 P/Share
|
|
Mar 16
2023
|
Sean A. Mc Carthy CEO |
SELL
Open market or private sale
|
Direct |
7,121
-1.8%
|
$7,121
$1.88 P/Share
|
|
Mar 16
2023
|
Carlos Campoy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,748
-4.37%
|
$1,748
$1.98 P/Share
|
|
Mar 16
2023
|
Christopher Ogden Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
516
-1.35%
|
$516
$1.98 P/Share
|